Cardiff Oncology, Inc. (CRDF) AI Stock Analysis

Cardiff Oncology, Inc. is a clinical-stage oncology company based in San Diego, California, developing treatments for cancer patients. Its primary focus is therapies targeting Polo-like Kinase 1 (PLK1), an enzyme involved in cell division and cancer progression. The lead program is onvansertib, an oral selective PLK1 inhibitor for anti-cancer therapeutics. Its pipeline also includes CY140, an inhibitor of PLK1, PLK2, and PLK3 in phase 1/2 studies for solid tumors and leukemias. Additionally, the company conducts trials in metastatic colorectal cancer and advances TROV-053 and TROV-054 through phase II and phase 1b/2 trials for prostate and colorectal cancers in combination with standard therapies.

Cardiff Oncology generated modest revenue over the observed periods, moving from $359,000 in FY2021 to $386,000 in FY2022, $488,000 in FY2023, and $683,000 in FY2024. In FY2025, revenue declined 13.2% to $593,000. Annual gross margin has consistently been 100.0%. Research and development expenses were $35.3M in FY2025, contributing to an operating margin of -8256.3% and a net loss of -$45.9M, or -$0.69 per share. Across the trailing twelve months ending June 30, 2026, revenue stood at $508,000 with an operating margin of -9245.2% and EPS of -$0.60. For the quarter ended June 30, 2026, quarterly revenue fell 14.1% year-over-year.

As of June 30, 2026, Cardiff Oncology held $34.5M in cash and short-term investments and $457,000 in total debt, resulting in net cash of $34.1M. Shareholders' equity was $26.5M against total assets of $37.3M, yielding a current ratio of 3.30 and a debt-to-equity ratio of 0.02. In FY2025, operating cash flow was -$37.9M and free cash flow was -$38.0M, with capital expenditures of $44,000. The company's share count increased 68.5% over the 5-year period.

At a last close price of $0.90 on October 16, 2026, Cardiff Oncology had a market capitalization of $70.1M and an enterprise value of $69.4M. Its price-to-sales ratio was 138.0x, compared to 4.1x for the median of its US-listed Healthcare peers. The company's price-to-book ratio stood at 3.9x, and its EV-to-revenue ratio was 136.6x. Over the past year, CRDF declined 59.8%, while the S&P 500 (SPY) returned 16.8%. Over five years, CRDF fell 85.9% compared to an 83.0% gain for the benchmark index.

Cardiff Oncology has 6 analyst recommendations: 2 Strong Buy, 1 Buy, 3 Hold, and no Sell or Strong Sell ratings. The mean price target is $5.81, representing 546.0% above the last close of $0.90. For the fiscal year ending December 31, 2026, analysts estimate an EPS of -$0.56 and revenue of $295,140. For the following fiscal year, 4 analysts project an EPS of -$0.54 and revenue of $320,830. The company beat EPS estimates in 3 of the last 4 quarters, and its next earnings date is November 5, 2026.

This page is an AI-written research summary of Cardiff Oncology, Inc. (CRDF). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: CRDF income statement, CRDF balance sheet, CRDF key metrics, CRDF analyst forecast, CRDF chart. See the CRDF stock overview for the latest quote and news.